Category: pyrazoles-derivatives

On April 1, 2021, Richards, Nicole; Lewis, Richard; Hamilton, Matthew; Ray, William; Alvarez, Fernando; Pfaffinger, Dana; Reyna, Naphtali; Cross, Jason; Ramaswamy, Suyambu Kesava Vijayan; Bardenhagen, Jennifer; Lightfoot, Yaima Luzardo; Acton, Paul; Goodwani, Sunil published a patent.Reference of 5-Methoxy-1H-pyrazole The title of the patent was Preparation of 1-[(4,5-dihydro-1H-pyrazol-1-yl)carbonyl]bicyclo[1.1.1]pentane derivatives as inhibitors of receptor interacting protein kinase for the treatment of disease. And the patent contained the following:

The is invention is related to the preparation of compounds I [X = a bond, carbamoyl, carbonyl, (un)substituted alkylene; R1a, R1b = independently H, (un)substituted alkyl; or R1aNR1b= (un)substituted heterocycloalkyl or heteroaryl; R2 = H, OH, CN, halo, NH2, etc.] or salts thereof which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer. Thus, Wittig reaction between 3,5-difluorobenzaldehyde and 2-(triphenylphosphoranylidene)acetaldehyde, cyclization of (E)-3-(3,5-difluorophenyl)-2-propenal with NH2NH2 and reaction of 5-(3,5-difluorophenyl)-4,5-dihydro-1H-pyrazole with 3-(methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid gave II. Exemplified compounds I were tested for their RIPK1 activity (data given for representative compounds I). The experimental process involved the reaction of 5-Methoxy-1H-pyrazole(cas: 215610-30-3).Reference of 5-Methoxy-1H-pyrazole

The Article related to dihydropyrazolylcarbonylbicyclopentane derivative preparation receptor interacting protein kinase 1 inhibitor, ripk1 inhibitor dihydropyrazolylcarbonylbicyclopentane derivative preparation antiinflammatory anticancer neurodegenerative disorder and other aspects.Reference of 5-Methoxy-1H-pyrazole

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Seela, Frank; Jawalekar, Anup M.; Sun, Lijuan; Leonard, Peter published an article in 2005, the title of the article was Oligonucleotides Containing Pyrazolo[3,4-d]Pyrimidines: 8-Aza-7-deazaadenines With Bulky Substituents in the 2- or 7-Position.Product Details of 85426-79-5 And the article contains the following content:

The synthesis of the 2′-deoxyadenosine analogs, e.g. I, modified at the 7- and/or 2-position is described. The effect of 7-chloro and 2-methylthio groups on the duplex stability is evaluated. For that, the nucleosides, e.g. I, were converted to the corresponding phosphoramidites, which were employed in the solid-phase oligonucleotide synthesis. In oligonucleotide duplexes, compound I forms stable base pairs with dT, of which the separated I-dT base pairs contribute stronger than that of the consecutive base pairs. Nucleoside II shows universal base pairing properties while its N8 isomer forms duplexes with lower stability. The experimental process involved the reaction of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine(cas: 85426-79-5).Product Details of 85426-79-5

The Article related to structure property thermodn thermal stability dna duplex synthesis, dna duplex synthesis thermal stability thermodn, oligonucleotide pyrazolopyrimidine azadeazaadenine synthesis dna duplex stability nucleoside phosphoramidite and other aspects.Product Details of 85426-79-5

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On September 23, 2021, Lancellotti, Patrizio; Oury, Cecile; Pirotte, Bernard; Musumeci, Lucia; Jacques, Nicolas; Goffin, Eric published a patent.Product Details of 85426-79-5 The title of the patent was Preparation of pyrimidine derivatives for prevention and treatment of Gram-negative bacterial infection, contamination and fouling. And the patent contained the following:

This invention relates to new pyrimidine derivatives I [X1 and X2 = (independently) N, (un)substituted CH (with the exception that if one of X1 or X2 is N, then the remaining of X1 or X2 = (un)substituted CH); Y = O or S; R1 and R2 = (independently) alkyl, cycloalkyl, aryl, etc.; R3-R7 = (independently) H, halo, alkyl, etc.] or pharmaceutically acceptable acid addition salts, together with a membrane penetrating agent, optionally with a detectable isotope and pharmaceutical composition for use in treatment or prevention of Gram-neg. bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of Gram-neg. biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. E.g., a multi-step synthesis of (1R,2S)-II, starting from 4,6-dichloro-2-(propylthio)pyrimidin-5-amine and methylamine, was disclosed. Antibacterial effects of representative compounds I together with Polymyxin B Nonapeptide (membrane penetrating agent) on Escherichia coli were examined (data given). A method of diagnosing or prognosing a Gram-neg. bacterial infection in a host mammal comprising using the pyrimidine derivatives I together with a membrane penetrating agent, was disclosed. The experimental process involved the reaction of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine(cas: 85426-79-5).Product Details of 85426-79-5

The Article related to pyrimidine derivative pyrrolopyrimidinamine phenylcyclopropyl preparation gram neg bacterial infection, antibacterial combination chemotherapy membrane penetrating agent pyrrolopyrimidinamine phenylcyclopropyl preparation and other aspects.Product Details of 85426-79-5

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Nicolaou, K. C.; Rhoades, Derek; Wang, Yanping; Totokotsopoulos, Sotirios; Bai, Ruoli; Hamel, Ernest published an article in 2015, the title of the article was Synthesis and Biological Evaluation of Novel Epothilone B Side Chain Analogues.Formula: C8H11BrN2O And the article contains the following content:

The design, synthesis, and biol. evaluation of a series of epothilone analogs with novel side chains equipped with an amino group are described. Their design facilitates potential conjugation to selective drug delivery systems such as antibodies. Their synthesis proceeded efficiently via Stille coupling of a readily available vinyl iodide and heterocyclic stannanes. Cytotoxicity studies and tubulin binding assays revealed two of these analogs, I (R = CF3, F), to be more potent than epothilones A-D and the anticancer agent ixabepilone, currently in clin. use. The experimental process involved the reaction of 5-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole(cas: 1187582-58-6).Formula: C8H11BrN2O

The Article related to epothilone b side chain analog preparation antitumor structure activity, tubulin binding epothilone b side chain analog, antibody-drug conjugates, anticancer agents, epothilones, organic synthesis, tubulin binding agents and other aspects.Formula: C8H11BrN2O

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On March 12, 2009, Demeese, Jason; Gaudino, John; Neitzel, Alicia Tarin; Lunghofer, Paul; Jeongbeob, Seo; Hongqi, Tian; Young, Wendy B.; Sutherlin, Daniel P. published a patent.HPLC of Formula: 924909-16-0 The title of the patent was Preparation of pyrazolopyridines as tyrosine kinase inhibitors. And the patent contained the following:

Title compounds[I, II; X = O, S, NR10; W = O, S, SO, SO2; R1 = H, alkyl, alkenyl, alkynyl, CONR10R11, (substituted) carbocyclyl, heterocyclyl, aryl, heteroaryl, etc.; R2 = H, CF3, cyano, NR10R11, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, etc.; R3 = (substituted) carbocyclyl, heterocyclyl, aryl, heteroaryl; R4 = H, F, Cl, Br, CF3, cyano, NR10R11, OR10, etc.; R10, R11 = H, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heteroaryl, etc.], were prepared as c-MET kinase inhibitors (no data). Thus, title compound (III) was prepared in 13 steps from 2,2-dimethyl-1,3-dioxane-4,6-dione, 1-(4-methoxybenzyl)-1H-pyrazol-5-amine, 1,2-difluoro-4-nitrobenzene, 1-(4-fluorophenyl)hydrazine hydrochloride, 1,3-dioxane-4,6-dione, and tert-Bu 4-hydroxypiperidine-1-carboxylate. The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).HPLC of Formula: 924909-16-0

The Article related to pyrazolopyridine preparation tyrosine kinase inhibitor, cmet kinase inhibitor piperidinyloxypyrazolopyridine preparation, cancer stroke diabetes hepatomegaly alzheimers treatment phenoxypyrazolopyridine preparation and other aspects.HPLC of Formula: 924909-16-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On June 2, 2011, Demeese, Jason; Gaudino, John; Neitzel, Alicia Tarin; Lunghofer, Paul; Seo, Jeongbeob; Tian, Hongqi; Young, Wendy B.; Sutherlin, Daniel P. published a patent.Formula: C14H13N3O2 The title of the patent was Preparation of pyrazolopyridines as tyrosine kinase inhibitors. And the patent contained the following:

Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathol. conditions are disclosed. Title compounds[I, II; X = O, S, NR10; W = O, S, SO, SO2; R1 = H, alkyl, alkenyl, alkynyl, CONR10R11, (substituted) carbocyclyl, heterocyclyl, aryl, heteroaryl, etc.; R2 = H, CF3, cyano, NR10R11, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, etc.; R3 = (substituted) carbocyclyl, heterocyclyl, aryl, heteroaryl; R4 = H, F, Cl, Br, CF3, cyano, NR10R11, OR10, etc.; R10, R11 = H, (substituted) alkyl, alkenyl, alkynyl, carbocyclyl, heteroaryl, etc.], were prepared as c-MET kinase inhibitors (no data). Thus, title compound (III) was prepared in 13 steps from 2,2-dimethyl-1,3-dioxane-4,6-dione, 1-(4-methoxybenzyl)-1H-pyrazol-5-amine, 1,2-difluoro-4-nitrobenzene, 1-(4-fluorophenyl)hydrazine hydrochloride, 1,3-dioxane-4,6-dione, and tert-Bu 4-hydroxypiperidine-1-carboxylate. The experimental process involved the reaction of 1-(4-Methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-ol(cas: 924909-16-0).Formula: C14H13N3O2

The Article related to pyrazolopyridine preparation tyrosine kinase inhibitor, cmet kinase inhibitor piperidinyloxypyrazolopyridine preparation, cancer stroke diabetes hepatomegaly alzheimers treatment phenoxypyrazolopyridine preparation and other aspects.Formula: C14H13N3O2

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On May 31, 2003, Kim, Dong Chan; Lee, Yeo Ran; Yang, Beom-Seok; Shin, Kye Jung; Kim, Dong Jin; Chung, Bong Young; Yoo, Kyung Ho published an article.Quality Control of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine The title of the article was Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors. And the article contained the following:

A series of 1,4,6-trisubstituted pyrazolo[3,4-d]pyrimidines capable of selectively inhibiting CDK2 activity were synthesized by derivatization at C-4, C-6 and N-1 with various amines and lower alkyl groups. For above synthetic compounds, biol. evaluation was carried out and structure-activity relationship was examined In the series, 4-anilino compounds exhibited better CDK2 inhibitory activity and antitumor activity compared to 4-benzyl compounds Two compounds having a 3-fluoroaniline group at C-4 showed comparable or superior CDK2 inhibitory activity to those of olomoucine and roscovitine as reference compounds In general, the unsubstituted compounds at N-1 possessed higher potency than the substituted compounds for the CDK2 inhibitory activity. As for EGFR inhibitory activity, most compounds did not have a significant activity. Two compounds exhibited potent cell growth inhibitory activity against human cancer cell lines, but their CDK2 inhibitory activities were slightly poorer than olomoucine. The experimental process involved the reaction of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine(cas: 85426-79-5).Quality Control of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine

The Article related to pyrazolopyrimidine preparation cyclin dependent kinase 2 inhibitor, cdk2 inhibitor pyrazolopyrimidine preparation, egfr inhibitor pyrazolopyrimidine preparation, antitumor agent pyrazolopyrimidine preparation and other aspects.Quality Control of 4-Chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On December 31, 2012, Ablajan, Keyume; Wang, Liju published an article.Synthetic Route of 36640-53-6 The title of the article was Convenient synthesis and characterization of hydrazone derivatives of 3-(2-naphthyl)-1-phenyl-pyrazole-4-carbaldehyde. And the article contained the following:

In order to obtain novel hydrazone derivatives containing pyrazole and thiazole rings which possess certain biol. activity, a series of 1-(3-β-naphthyl-1-phenylpyrazole-4-methylene)-2-(4-arylthiazol-2-yl)hydrazones I(R = Ph, 4-Me-C6H4, 4-MeO-C6H4, 4-Cl-C6H4, 4-NO2-C6H4, 4-Br-C6H4, 2-naphthyl) were synthesized via two different methods including multi step reactions and one-pot synthetic route using 3-β-naphthyl-1-phenyl-pyrazole-4-carbaldehyde as a starting intermediate. The products were obtained in good yield under ultrasonic irradiation condition rather than heating. The structures of products were characterized by 1H NMR, MS and elemental anal. The preliminary bioassay showed that compounds I(R = 4-Me-C6H4, 4-Cl-C6H4) possess obvious protective effects on the PC12 cells injury induced by H2O2. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Synthetic Route of 36640-53-6

The Article related to naphthylphenylpyrazolemethyleneaiylthiazolylhydrazone preparation pc12 cell protection, naphthylphenylpyrazole carbaldehyde preparation hydrazinecarbothioamide arylcarbonylmethyl bromide cyclocondensation and other aspects.Synthetic Route of 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On May 31, 2011, Wenglowsky, Steve; Ren, Li; Ahrendt, Kateri A.; Laird, Ellen R.; Aliagas, Ignacio; Alicke, Bruno; Buckmelter, Alex J.; Choo, Edna F.; Dinkel, Victoria; Feng, Bainian; Gloor, Susan L.; Gould, Stephen E.; Gross, Stefan; Gunzner-Toste, Janet; Hansen, Joshua D.; Hatzivassiliou, Georgia; Liu, Bonnie; Malesky, Kim; Mathieu, Simon; Newhouse, Brad; Raddatz, Nicholas J.; Ran, Yingqing; Rana, Sumeet; Randolph, Nikole; Risom, Tyler; Rudolph, Joachim; Savage, Scott; Selby, LeAnn T.; Shrag, Michael; Song, Kyung; Sturgis, Hillary L.; Voegtli, Walter C.; Wen, Zhaoyang; Willis, Brandon S.; Woessner, Richard D.; Wu, Wen-I.; Young, Wendy B.; Grina, Jonas published an article.Computed Properties of 1186608-73-0 The title of the article was Pyrazolopyridine Inhibitors of B-RafV600E. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors. And the article contained the following:

The V600E mutation of B-Raf kinase results in constitutive activation of the MAPK signaling pathway and is present in approx. 7% of all cancers. Using structure-based design, a novel series of pyrazolopyridine inhibitors of B-RafV600E was developed. Optimization led to the identification of 3-methoxy pyrazolopyridines 17 and 19, potent, selective, and orally bioavailable agents that inhibited tumor growth in a mouse xenograft model driven by B-RafV600E with no effect on body weight On the basis of their in vivo efficacy and preliminary safety profiles, 17 and 19 were selected for further preclin. evaluation. The experimental process involved the reaction of 3-Methyl-1H-pyrazolo[3,4-b]pyridin-5-amine(cas: 1186608-73-0).Computed Properties of 1186608-73-0

The Article related to pyrazolopyridine derivative braf kinase inhibitor preparation antitumor pharmacokinetics toxicity, b-rafv600e, mapk pathway, amorphous spray-dried dispersion, pyrazolopyridine, targeted therapy and other aspects.Computed Properties of 1186608-73-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On December 31, 2007, Shelke, S. N.; Dalvi, N. R.; Gill, C. H.; Karale, B. K. published an article.Synthetic Route of 36640-53-6 The title of the article was Synthesis of various heterocycles from 3-(2-naphthalenyl)-1-phenyl-1H-pyrazole-4-carboxaldehyde. And the article contained the following:

Condensation of the title compound (I) with 2′-hydroxyacetophenones gave propenones II (R1 = H, Cl, Me; R2, R4 = H, Me; R3 = H, Cl, Me, Et, Br, F), which reacted with hydrazine to give pyrazolines III and with iodine in DMSO to give chromones IV. Reaction of IV with hydrazine gave bipyrazoles V. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Synthetic Route of 36640-53-6

The Article related to pyrazolecarboxaldehyde condensation hydroxyacetophenone, pyrazolylpyrazoline aryl derivative preparation, pyrazolylchromone aryl derivative preparation, bipyrazole aryl derivative preparation and other aspects.Synthetic Route of 36640-53-6

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics